Biocryst Pharmaceuticals Inc (BCRX) Stock Price & Analysis
Biocryst Pharmaceuticals Inc (BCRX) fell 1.19% to USD 8.33 as of June 10, 2026 at 05:33 UTC, according to Nexqual real-time market data.
BCRX last closed at USD 8.43; the session ranged USD 8.33–8.63 on volume of 3,796,784 shares. Market capitalization is $2.12B, with a 52-week range of USD 6–11.07 (NMS). Source: Nexqual, June 10, 2026 at 05:33 UTC.
Key Statistics (as of June 10, 2026 at 05:33 UTC)
| Price | USD 8.33 |
|---|---|
| Change | ▼ 1.19% (down) |
| Previous Close | USD 8.43 |
| Open | USD 8.52 |
| Day Range | USD 8.33 – 8.63 |
| 52-Week Range | USD 6 – 11.07 |
| Volume | 3,796,784 shares |
| Market Cap | $2.12B |
| Exchange | NMS |
Technical Analysis (BCRX)
Nexqual's technical model rates BCRX "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:33 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.8 (neutral) |
| vs SMA50 | Below (USD 9.03) |
| MACD | -0.16 (negative) |
Analyst Ratings (BCRX)
Wall Street analysts rate BCRX "None" based on 10 analysts, with a mean price target of USD 21.3 (range USD 13–32), per Nexqual as of June 10, 2026 at 05:33 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 21.3 |
| High Target | USD 32 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (BCRX)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 0.25 |
| Revenue Estimate | $185.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.14 vs est 0.11 ▲ beat |
| 2025-12-31 | USD 0.21 vs est 0.07 ▲ beat |
| 2025-09-30 | USD 0.16 vs est 0.07 ▲ beat |
| 2025-06-30 | USD 0.04 vs est 0.03 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:33 UTC.
Financials & Fundamentals (BCRX)
| Total Revenue | $885.72M |
|---|---|
| Revenue Growth (YoY) | +7.50% |
| Gross Margin | +76.63% |
| Operating Margin | -2.45% |
| Profit Margin | -51.71% |
| Current Ratio | 1.91 |
| Total Cash | $238.40M |
| Total Debt | $858.08M |
| Free Cash Flow | $264.38M |
Source: Nexqual, June 10, 2026 at 05:33 UTC.
Financial Health Score (BCRX)
Nexqual rates Biocryst Pharmaceuticals Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 05:33 UTC.
| Growth | Strong — Revenue +94% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 77%, operating -2% |
| Balance Sheet | Mixed — $238M cash vs $858M debt |
| Cash Flow | Strong — FCF $264M, 30% margin |
| Efficiency | Mixed — No data |
Ownership (BCRX)
| Insider Ownership | +1.15% |
|---|---|
| Institutional Ownership | +100.98% |
| Shares Outstanding | 254.16M |
| Float | 220.85M |
| Short % of Float | +14.53% |
Source: Nexqual, June 10, 2026 at 05:33 UTC.
Leadership (BCRX)
Biocryst Pharmaceuticals Inc is led by Charles K. Gayer (age 54), CEO, President & Director, per Nexqual as of June 10, 2026 at 05:33 UTC.
| CEO, President & Director | Charles K. Gayer (age 54) |
|---|---|
| CFO & Head of Corporate Development | Babar Ghias (age 46) |
| Chief Strategy Officer | Philip George |
Major Backers & Investors (BCRX)
Notable institutional backers of Biocryst Pharmaceuticals Inc include RA Capital Management, L.P., Deerfield Management Company, L.P, TCG Crossover Management, LLC, according to Nexqual as of June 10, 2026 at 05:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 6.23% |
| Deerfield Management Company, L.P | 5.92% |
| TCG Crossover Management, LLC | 4.34% |
| Janus Henderson Group PLC | 3.51% |
| Perceptive Advisors Llc | 2.92% |
| Vestal Point Capital, LP | 2.76% |
| abrdn Healthcare Investors | 1.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.04% |
| BlackRock | 11.68% |
| State Street | 7.73% |
Source: Nexqual, June 10, 2026 at 05:33 UTC.
From Biocryst Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the United States and Europe, and five full years of commercialization experience with ORLADEYO in the United States from 2021 through 2025, we anticipate that the global commercial market for ORLADEYO has the potential to reach a global peak of $1 billion in annual net ORLADEYO revenues.
- In addition, we rely upon trade secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology, and products and product candidates.
- Our ability to maintain and solidify our proprietary position for our technology will depend on our success in obtaining effective patent claims and enforcing those claims once granted.
- We own or have rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate to compounds we are developing.
Partnerships
- Collaborations, License and Other Relationships ORLADEYO Torii Pharmaceutical Co., Ltd. ( " Torii " ) On November 5, 2019, we entered into a Commercialization and License Agreement with Torii (the "Original Torii Agreement"), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.
- On October 1, 2025, we also entered into a supply agreement with BioCryst Ireland, pursuant to which we will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | USD 21.84 | ▲ 1.3% |
| AGEN | Agenus Inc. | USD 3.11 | ▼ 3.72% |
| INO | Inovio Pharmaceuticals, Inc. | USD 1.1 | ▲ 2.8% |
| VXRT | Vaxart, Inc. | USD 0.58 | ▼ 6.45% |
| CERS | Cerus Corporation | USD 2.58 | ▼ 4.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:33 UTC. This page is informational and not investment advice.